Filing Flows › Comparisons › NEOG vs MYGN
Neogen vs Myriad Genetics: NEOG and MYGN compared
Neogen is the larger company: $223M of revenue in its latest quarter (Q1 FY27) against $203M for Myriad Genetics (Q3 2026). Neogen is growing faster (+6% against -2% a year earlier). Neogen is more profitable, with an operating margin of -0.8% against -19.7%.
Where the money goes: NEOG and MYGN
Neogen (NEOG) · Q1 FY27
Neogen, Q1 FY27: revenue $223M (+6% year over year), operating margin -0.8%, net loss $11.9M, operating cash flow $12.9M. The chart follows the revenue to costs, profit and cash.
Myriad Genetics (MYGN) · Q3 2026
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Neogen (NEOG) | Myriad Genetics (MYGN) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q3 2026 |
| Revenue | $223M | $203M |
| Revenue growth, Y/Y | +6% | -2% |
| Operating margin | -0.8% | -19.7% |
| Net earnings | −$11.9M | −$43.9M |
| Net margin | -5.3% | -21.7% |
| Operating cash flow | $12.9M | −$6.5M |
| Free cash flow | $4.7M | — |
| Market value | $2.6B | — |
| Analysts’ mean target | $14.00 | — |
Where the revenue comes from
Neogen
- Product: $196M (88%)
- Service: $26.8M (12%)
Myriad Genetics
- Cancer Care Continuum: $124M (61%)
- Mental Health: $39.5M (19%)
- Prenatal Health: $39.3M (19%)
Questions
Which is bigger, Neogen or Myriad Genetics?
Neogen is the larger company: $223M of revenue in its latest quarter (Q1 FY27) against $203M for Myriad Genetics (Q3 2026).
Is Neogen or Myriad Genetics growing faster?
Neogen is growing faster (+6% against -2% a year earlier).
Which is more profitable, Neogen or Myriad Genetics?
Neogen is more profitable, with an operating margin of -0.8% against -19.7%.
More: Neogen earnings · how Neogen makes money · Myriad Genetics earnings · how Myriad Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 7, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.